.Attributes Medicine, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) treatment of clients along with HER2+ state-of-the-art breast cancer cells and energetic or even secure mind metastases presented regular intracranial activity as well as wide spread efficacy of T-DXd.